June 9, 2023

Te­va is the lat­est in a long list of drug­mak­ers plac­ing re­stric­tions around the fed­er­al 340B pro­gram which pro­vides dis­count­ed drugs for low-in­come Amer­i­cans. Ac­cord­ing

Ei­sai has fall­en vic­tim to a ran­somware at­tack, the com­pa­ny re­port­ed Tues­day, as ex­perts warn that drug­mak­ers are in­creas­ing­ly be­ing tar­get­ed by hack­ers. The in­ci­dent

A new Bris­tol My­ers Squibb cell man­u­fac­tur­ing site that is ex­pect­ed to make the CAR-T ther­a­py Breyanzi has re­ceived FDA ap­proval to start pro­duc­tion. The

Phar­ma com­pa­nies are slow­ly shift­ing to dig­i­tal ad­ver­tis­ing, but that doesn’t mean they are giv­ing up on TV ads any­time soon, ac­cord­ing to a re­cent

As­traZeneca says its add-on pill for a rare blood dis­or­der known as parox­ys­mal noc­tur­nal he­mo­glo­bin­uria, or PNH, helped pa­tients al­ready tak­ing Ul­tomiris or Soliris pro­duce

Abeona Ther­a­peu­tics pushed back plans to sub­mit its gene ther­a­py for a rare skin con­di­tion af­ter the FDA asked the com­pa­ny for more da­ta about

Share­hold­ers of Nordic Nanovec­tor did not like the first merg­er part­ner the Nor­we­gian biotech chose last fall. So the com­pa­ny went back to the draw­ing

The De­part­ment of Health and Hu­man Ser­vices on Fri­day re­vealed its lat­est round of coin­sur­ance sav­ings for se­niors on drugs with prices ris­ing faster than

With a Phase III tri­al now un­der­way for a once-week­ly, long-act­ing ver­sion of the an­tipsy­chot­ic med risperi­done, Lyn­dra Ther­a­peu­tics is eye­ing a large Se­ries D

When Disc Med­i­cine closed a $62.5 mil­lion raise led by Bain Cap­i­tal ear­li­er this year, the biotech’s CEO John Quisel point­ed to the stream of